Citations

Mayo Clinic

Clear

11 citation(s) found for "Murphy, Michael".

Comparison of Patients with Primary Hyperoxaluria 1 and Late-Stage CKD from the BONAPH1DE Registry and ILLUMINATE-C Lumasiran Trial
Baum, Michelle A. , Ben‐Shalom, Efrat , Belostotsky, Vladimir , Sellier-Leclerc, A.L., Du, W. J. , Kauf, Teresa L., Murphy, Michael Desmond, Groothoff, Jaap W. , Lieske, John C. , Knauf, Felix , Sellier‐Leclerc, Anne‐Laure , Du, Weiming, Callanan, Mary B.

Journal of the American Society of Nephrology | December 1, 2025 | Volume: 36 | Issue: 10S | Pages: No page available

10.1681/asn.2025b26anqr1 Get It

Final 60-Month Efficacy, Safety, and Kidney Stone Outcomes of a Phase 3 Trial of Lumasiran for Primary Hyperoxaluria Type 1 in Infants and Young Children
Sas, David J. , Michael, Mini , Frishberg, Yaacov, Ben‐Shalom, Efrat , Shasha‐Lavsky, Hadas , Sellier-Leclerc, A.L., Hogan, Julien, Du, W. J. , Murphy, Michael Desmond, Kaspar, Cristin , Magen, Daniella , Hayes, Wesley Nathan , Sellier‐Leclerc, Anne‐Laure , Hogan, Julien , Du, Weiming

Journal of the American Society of Nephrology | October 23, 2025 | Volume: 36 | Issue: 10S | Pages: No page available

10.1681/asn.2025v7er7rv3 Get It

Assessment of Cutaneous and Mucosal Direct Immunofluorescence Testing Practices in the US
Lehman, Julia S. , Leiferman, Kristin M. , Brinster, Nooshin K. , Camilleri, Michael , Cocks, Margaret , Grover, Raminder, Jedrych, Jaroslaw , Kuechle, Melanie K., McNiff, Jennifer M. , Murphy, Michael J. , Nousari, Carlos H., Zone, John J. , Bridges, Alina G. , Lehman, Julia S , Fernandez, Anthony P , Culton, Donna Aline , Kim, Randie H. , North, Jeffrey P. , Stoff, Benjamin K. , Elenitsas, Rosalie , Fung, Maxwell A. , Moshiri, Ata S. , Motaparthi, Kiran , Shalin, Sara C.

JAMA Dermatology | April 4, 2025 | Volume: 161 | Issue: 7 | Pages: 747

10.1001/jamadermatol.2025.0339 | PMID 40172897 Get It

ImportanceDirect immunofluorescence (DIF) testing has been an important ancillary tool for the diagnosis of various inflammatory mucocutaneous conditions for more than 50 years. Current DIF test panels are based on historical clinical descriptions; few studies have rigorously addressed preanalytical, analytical, and/or postanalytical aspects, and even fewer have been replicated or validated. Recent unresolved key issues include whether DIF testing and test panels should be triaged or truncated based on clinical indication or histopathologic findings.ObjectiveTo assess levels of consensus regarding practical aspects of DIF testing among immunodermatology testing specialists in the US.Design, Setting, and ParticipantsUsing modified Delphi methods with a priori characterized criteria, a survey containing 54 statements pertaining to DIF testing was created and distributed to assess consensus. Statements not initially reaching consensus were discussed in 2 live virtual sessions, which were supplemented by relevant literature review and free-text survey comments. These statements were then reassessed in a second survey. Immunodermatology testing specialists in US academic institution–based and independent laboratories were invited based on serving as immunodermatology laboratory medical directors, authoring pertinent literature, or delivering relevant talks at major conferences or by referral. The first survey was conducted from January to February 2024, and the second survey was conducted from March to April 2024.Main Outcomes and MeasuresThe primary measured outcome was degree of consensus for various DIF testing practice, including DIF testing triage by histopathology/dermatopathology findings and DIF testing panel tailored truncations by clinical indication.ResultsA total of 23 respondents to the survey invitation had a mean (SD) of 18.5 (11.1) years and median (range) of 20.0 (1.5-46.0) years in immunodermatology laboratory practice. Consensus was achieved for 46 of 54 statements (85.2%) in the initial survey and for an additional 4 statements in the second survey (50 of 54 [92.6%]). Strong consensus was found against tailored truncation of DIF panel based on the clinical indication in the first survey round. The general acceptability of triaging specimens for DIF testing based on histopathology findings remained without consensus after both surveys.Conclusions and RelevanceOverall, participating US specialists in immunodermatology laboratory testing agreed on many practical aspects of DIF testing, including matters not queried previously. The findings also revealed areas of continued controversy and identified issues for prioritized future study.
Why do people still make anti‐D over 50 years after the introduction of Rho(D) immune globulin? A Biomedical Excellence for Safer Transfusion (BEST) Collaborative study
DelBaugh, Regina M. , Murphy, Michael , Staves, Julie , Fachini, Roberta , Hands, Katie , Bub, Carolina Bonet , Cohn, Claudia S. , Cox, Cody A., Ziman, Alyssa , Fermon, Erica J., Peters, Jessica, Collaborative, BEST foRmation of Anti‐D After Rhogam (RADAR) Study Investigators and the Biomedical Excellence for Safer Transfusion (BEST), Callum, Jeannie , Murphy, Michael , Wendel, Silvano , Bonet-Bub, Carolina , Cohn, Claudia S , Jacquot, Cyril , Hasan, Rida A , Lu, Wen , Juskewitch, Justin E , Raval, Jay S , Fung, Mark K , Ziman, Alyssa , Dunbar, Nancy M , Kutner, José Mauro , Cox, Cody A., Jacquot, Cyril , Hasan, Rida A. , Lu, Wen , Juskewitch, Justin E. , Raval, Jay S. , Rollins‐Raval, Marian A. , Gorlin, Jed B. , Dunbar, Nancy M. , Collaborative, BEST foRmation of Anti‐D After Rhogam (RADAR) Study Investigators and the Biomedical Excellence for Safer Transfusion (BEST)

Transfusion | March 10, 2025 | Volume: 65 | Issue: 5 | Pages: 957-967

10.1111/trf.18202 | PMID 40059673 Get It

Abstract Background Rho(D) immune globulin (RhIg) is used to reduce RhD alloimmunization in pregnancy. This study describes potential causes for RhD alloimmunization after the development and implementation of RhIg. Study Design and Methods This retrospective descriptive study investigated RhD‐negative patients born in 1965–2005 with anti‐D newly identified during 2018–2022. Transfusion, pregnancy, intravenous drug abuse, and transplantation were considered potential alloimmunization sources. Results There were 1200 study patients (852 females; 348 males) at 30 institutions in 5 countries (USA, Canada, UK, New Zealand, Brazil). Most patients had a single potential source of alloimmunization identified (857/1200, 71%), most commonly pregnancy among females (537/852, 63%) and transfusion among males (180/348, 52%). When multiple potential sources were included, males were more likely than females to have a history of transfusion (235/348 [68%] vs. 149/852 [17%], p < .0001) and confirmed or suspected intravenous drug abuse (100/348 [29%] vs. 138/852 [16%], p < .0001). Among females with a history of pregnancy, 119/718 (17%) had healthcare access issues, 120/718 (17%) had pregnancy in a country where they may not have received RhIg, and 21/718 (3%) refused RhIg. Among patients with a history of transfusion, males were more likely than females to have received RhD‐positive red blood cells or whole blood (143/235 [61%] vs. 30/149 [20%], p < .0001) and/or platelets (84/235 [36%] vs. 19/149 [13%], p < .0001). Discussion Pregnancy was the most frequently identified potential source of RhD alloimmunization among females. Transfusion was most frequent in males. Intravenous drug abuse as a common potential source among patients with RhD alloimmunization merits further study.
A global analysis of the use of immunoglobulin, shortages in supply, and mitigating measures: A survey of hospital providers (a BEST Collaborative study)
So‐Osman, Cynthia , Delaney, Meghan , Murphy, Michael , Sasongko, Praiseldy Langi , Tinmouth, Alan , Collaborative, the Best ImmunoGlobulin (BIG) Study Group* the Biomedical Excellence for Safer Transfusion, Fung, Mark K , Lu, Wen , Murphy, Michael , Sasongko, Praiseldy Langi , Tiberghien, Pierre , Collaborative, the Best ImmunoGlobulin (BIG) Study Group* the Biomedical Excellence for Safer Transfusion

Transfusion | March 22, 2024 | Volume: 64 | Issue: 5 | Pages: 775-783

10.1111/trf.17801 | PMID 38516758 Get It

AbstractBackgroundImmunoglobulin (IG) therapy is widely used to treat primary and secondary immune deficiencies and as immunomodulatory agent for various disorders. There is great concern that shortages of IG may rise, potentially affecting medical treatment options.Study Design and MethodsAn international survey was developed to study how intravenous immunoglobulins (IVIGs) are used and managed within hospitals in case of shortages. Study data were collected and managed using REDCap electronic data capture tools hosted by the Biomedical Excellence for Safer Transfusion (BEST) Collaborative. The survey was directed to hospital pharmacists and blood bank transfusion professionals and disseminated through members of the BEST Collaborative network.ResultsSurvey respondents from institutions in the USA, Canada, Europe, Japan, and Australia (n = 13) confirmed that the primary specialties utilizing IG are neurology, hematology, and immunology. More than 60% of respondents reported IG supply shortages, but mitigation strategies were not well developed.DiscussionAs IG is the leading driver in plasma demand, more studies are needed to understand current and future demand for IG from the clinical perspective. Necessity lies in establishing clinical guidance to address shortages.
Pain Control and Satisfaction With Peripheral Nerve Blocks for Upper Extremity Surgery
Wu, Caroline M., Gary, Cyril S., Karim, Kristin E. , Sanghavi, Kavya K. , Murphy, Michael S, Hobelmann, J. Todd, Giladi, Aviram M.

HAND | December 21, 2022 | Volume: 19 | Issue: 4 | Pages: 555-561

10.1177/15589447221141482 | PMID 36544240 Get It

Background: Regional anesthesia (“block”) is an important component of upper extremity (UE) surgery pain control. However, little is known about patient experience related to perioperative opioid use. This study assessed patient-reported pain control and satisfaction with UE blocks and evaluated how opioid consumption impacted these outcomes before the block “wore off.” Methods: A postoperative phone survey was administered to patients who underwent outpatient UE surgery at a surgery center for more than 16 months. It assessed pain scores (scale 1-10), satisfaction with block duration (scale 1-5), duration until return of UE function, and opioid consumption. Analyses used Mann-Whitney U tests, Fisher exact tests, and bivariate and multivariable linear and ordered logistic regressions to understand relationships between opioid use and outcomes. Results: A total of 509 patients (61%) completed the survey, and 441 (88%) were satisfied with block duration. Initial and final pain scores were significantly higher in patients who took opioids prior to the block wearing off (6 and 4.5, P = .04 and 3.5 and 2, P = .002, respectively). Although satisfaction with block duration was not different in group comparisons (ie, patients who premedicated vs those who did not), in a multivariable analysis, patients who premedicated with opioids had 78% increased odds of reporting the highest level of satisfaction compared with the lower 4 levels ( P = .03). Conclusions: Upper extremity blocks are associated with high overall patient satisfaction and postsurgical pain control. Premedicating before the block wears off may increase patient satisfaction with block duration even if pain is not notably impacted.
Laryngotracheal Mucosal Surface Expression of Candidate Biomarkers in Idiopathic Subglottic Stenosis
Liu, Melissa M. , Motz, Kevin , Murphy, Michael K. , Yin, Linda X. , Ding, Dacheng , Gelbard, Alexander , Hillel, Alexander T. , Motz, Kevin M , Yin, Linda X , Gelbard, Alexander

The Laryngoscope | May 5, 2020 | Volume: 131 | Issue: 2 | Pages: 342-349

10.1002/lary.28712 | PMID 32369195 Get It

ObjectivesIdiopathic subglottic stenosis (iSGS) is an inflammatory process leading to fibrosis and narrowing of the laryngotracheal airway. There is variability in patient response to surgical intervention, but the mechanisms underlying this variability are unknown. In this pilot study, we measure expression of candidate targets at the mucosal surface of the subglottis in iSGS patients. We aim to identify putative biomarkers for iSGS that provide insights into the molecular basis of disease progression, yield a gene signature for the disease, and/or predict a response to therapy.Study DesignIn vitro comparative study of human cells.MethodsLevels of candidate transcripts and proteins were measured in healthy and stenotic laryngotracheal tissue specimens taken from the mucosal surface in 16 iSGS patients undergoing endoscopic balloon dilation. Pre‐ and post‐operative pulmonary function test and patient reported voice and breathing outcomes were also assessed. Unsupervised clustering was used to define patient subgroups based on expression profile.ResultsPulmonary function and voice and breathing outcome metrics demonstrated significant post‐operative improvement. Transcript levels of αSMA, CCL2, COL1A1, COL3A1, FN1, IFNG, and TGFB1 and protein levels of CCL2, IFNG, and IL‐6 were significantly upregulated in stenotic as compared to healthy tissues. Marked heterogeneity was observed in the patterns of expression of candidate markers across individuals and tissue types. Patient subgroups defined by expression profile did not show a statistically significant difference in dilation interval.ConclusionPro‐inflammatory and pro‐fibrotic pathways are significantly upregulated along the mucosal surface of stenotic laryngotracheal tissues, and CCL2 and IFNG merit further investigation as potential iSGS biomarkers.Level of Evidence4 Laryngoscope, 131:342–349, 2021
Abstract PR01: Oncogenic Kras-induced mitochondrial oxidative stress in pancreatic acini modulates the formation of precancerous lesions through autocrine EGFR signaling
Doeppler, Heike, DelGirono, Kathleen E., Störz, Peter , Liou, Geou‐Yarh , Döppler, Heike, Crawford, Howard C. , Murphy, Michael P.

Cancer Research | May 20, 2016 | Volume: 76 | Issue: 3_Supplement | Pages: PR01-PR01

10.1158/1538-7445.fbcr15-pr01 Get It

Abstract The development of pancreatic cancer requires both obtain of oncogenic Kras mutations and up-regulation of growth factor signaling. However, how oncogenic Kras regulates growth factor signaling in pancreatic cancer development is still unclear. Using a transgenic mouse model harboring an oncogenic Kras mutation and a 3D organoid explant culture of primary pancreatic acini, we here show that expression of mutant Kras in pancreatic acinar cells alters their mitochondrial metabolism, resulting in increased generation of mitochondrial reactive oxygen species (mROS). We further demonstrate that mROS induced by oncogenic Kras is required for transdifferentiating acinar cells to a duct-like phenotype and eventually progression to pancreatic intraepithelial neoplasia (PanIN), the most common precursor lesions of pancreatic ductal adenocarcinoma (PDAC). This transdiffentiation process is mediated by increased levels of epidermal growth factor receptor (EGFR) as well as its ligands, EGF and TGFα, through activation of the ROS-receptive transcription factors, NF-κB1 and NF-κB2. In Kas transgenic mice, the interception of KrasG12D-mediated generation of mROS significantly reduced the formation of pre-neoplastic lesions. Hence, our data provide mechanistic insight of how oncogenic Kras mutant crosstalks with growth factor signaling to cause the formation of pancreatic cancer. Citation Format: Geou-Yarh Liou, Heike Doeppler, Kathleen E. DelGirono, Howard C. Crawford, Michael P. Murphy, Peter Storz. Oncogenic Kras-induced mitochondrial oxidative stress in pancreatic acini modulates the formation of precancerous lesions through autocrine EGFR signaling. [abstract]. In: Proceedings of the Fourth AACR International Conference on Frontiers in Basic Cancer Research; 2015 Oct 23-26; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2016;76(3 Suppl):Abstract nr PR01.
Peri-operative complications in pediatric and adolescent shoulder arthroscopy
Lewallen, Laura, Murphy, Michael, Dahm, Diane L., McIntosh, Amy L. , Edmonds, Eric W.

Journal of Children's Orthopaedics | May 31, 2014 | Volume: 8 | Issue: 4 | Pages: 341-344

10.1007/s11832-014-0595-y | PMID 24880815 Get It

Background Shoulder arthroscopy is not common in the pediatric and adolescent population, but the frequency may be on the rise. The purpose of the study was to determine the incidence of acute complications of arthroscopic shoulder surgery in children and adolescents. Methods A retrospective, cross-sectional review was performed identifying patients aged 18 years or less who underwent an arthroscopic shoulder procedure from 1997 to 2009 at Institution 1 and 2007 to 2010 at Institution 2. Exclusion criteria included open procedures and missing records. Demographic and surgical data were collected, including intra-operative and post-operative complications during the first 6 months. The complications were divided into minor (no secondary treatment) and major (secondary treatment rendered). Results Two hundred children, mean age 15.9 years, met criteria and 73 % were boys. All procedures were performed under general anesthesia, but 51 % included inter-scalene regional anesthesia. There were 16 (8.0 %) total complications recorded. Major complications occurred in five (2.5 %) patients, including two tendinitis/bursitis requiring injections, one broken pain pump catheter requiring an accessory incision to retrieve, one pain control readmission, and one laceration of the cephalic vein requiring ligation. Minor complications occurred in 11 (5.5 %) patients, including allergic reactions, transient dysesthesias, headaches, bronchitis, syncope, transient hypotension, and uvula swelling. Conclusion Although we found no seriously deleterious outcomes, it is important to recognize that an additional service was rendered for 2.5 % of children undergoing shoulder arthroscopy. The events that did occur may be preventable and this study should serve as a baseline to improve quality and safety of shoulder arthroscopy in the pediatric population.